SLFN11 and Familial prostate cancer: SLFN11 was identified in 2012 as a prognostic marker for response to DNA damaging agents in-silico [6]) and was subsequently found to affect treatment response in brain and prostate cancer cells through its role in replication checkpoint maintenance and homologous recombination repair [1].